Technology
From biological signal to actionable information.
GLIA is translating its microRNA biomarker research into a portable point-of-care platform designed for rapid testing from a small blood sample.
The biomarker panel
GLIA has developed a proprietary microRNA biomarker approach based on research examining biological responses following traumatic brain injury (TBI).
The biomarker panel has been evaluated across multiple human studies and cohorts, generating peer-reviewed publications in the Journal of Clinical Neuroscience.
Platform Design
Point-of-care translation
GLIA is translating this biomarker science into a portable electrochemical point-of-care platform.
The development objective is rapid analysis from a small blood sample using a disposable test format and portable reader.
Intended Platform Specifications
Sample Type
Target sample format: small-volume whole blood collected by fingerstick or venepuncture. The final pre-analytical workflow remains under development.
Time to Result
Target sample-to-result time: approximately 20 minutes. This remains a development objective and has not yet been clinically validated.
Biomarker Panel
Seven-marker circulating miRNA panel supported by human research. Analytical performance and clinical utility remain subject to further validation.
Cartridge Development
Cartridge configuration, reagent integration and storage requirements are being optimised as part of the current development programme.
Data & Connectivity
Reader and data-management architecture are under development. Final connectivity features have not yet been locked.
Regulatory Pathway
GLIA is undertaking regulatory planning for Australia, the United States and Europe. Final intended use, regulatory classification, performance requirements and clinical claims will be determined through product development, analytical and clinical validation, and regulatory engagement.
Intended Clinical Value
Complementing TBI Decision-Making
GLIA NeuroTESTA is being developed to add objective molecular information alongside established approaches to TBI assessment. Clinical examination, symptom assessment, cognitive testing, imaging and biomarkers provide different information about brain injury.
GLIA is investigating whether its miRNA panel can contribute additional biological information relevant to acute assessment, prognosis and longitudinal recovery. These potential applications require further prospective clinical validation.
Sport
Potential future application: objective biological information following suspected concussion and during recovery, alongside established concussion and return-to-play protocols.
Defence
Potential future application: biological assessment following blast or other head-injury exposure in operationally relevant environments.
Emergency department
Potential future application: adjunctive biological information in acute mTBI assessment. Specific clinical claims will be defined through validation and regulatory engagement.
Remote & Austere Settings
Potential future application: near-patient biological assessment where access to conventional laboratory infrastructure is limited.
Explore further
Related topics
TBI Biomarkers
The science supporting objective molecular investigation of brain injury.
Learn more →
microRNA Science
Circulating miRNAs being investigated as molecular indicators associated with TBI and recovery.
Learn more →
Sport
Potential future application of objective biological assessment alongside established concussion protocols.
Learn more →
Defence
Investigating portable biological assessment for blast and other head-injury exposures.
Learn more →
Objective Brain Injury Diagnostics — Field to Clinic
GLIA NeuroTESTA is in active development. GLIA is seeking clinical, research and strategic partners to support analytical validation, clinical studies, product development and the path toward regulatory clearance.